Bicycle Therapeutics to Present on BT5528, a Bicycle Toxin Conjugate Targeting EphA2 for the Treatment of Solid Tumors, at World ADC 2019
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Mar 5, 2019--Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic pe…
